Proteinqure
Computational protein design.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $11.0m | Series A | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 |
|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 |
| % growth | - | 13 % | - |
| EBITDA | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 |
| EV | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 |
Source: Dealroom estimates
Related Content
ProteinQure is a biotechnology company specializing in the computational design of peptides for precise tissue-specific therapeutic delivery. Operating in the precision medicine market, ProteinQure serves pharmaceutical companies and research institutions looking to enhance the efficacy of their treatments while minimizing side effects. The company's proprietary peptides are designed to deliver therapeutic payloads directly to disease-inducing cells via receptor-mediated endocytosis, ensuring targeted treatment. ProteinQure's business model revolves around partnerships and collaborations with pharmaceutical firms, generating revenue through licensing agreements and milestone payments. By leveraging a cross-disciplinary team of experts in Experimental Biology, Software Engineering, Machine Learning, and Computational Biology, ProteinQure aims to transform drug development and offer new hope to patients with previously untreatable diseases.
Keywords: computational peptides, tissue-specific delivery, precision medicine, therapeutic payloads, receptor-mediated endocytosis, drug discovery, biotechnology, pharmaceutical partnerships, targeted treatment, cross-disciplinary team.